Division of Dermatology, Department of Medicine, and.
Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Blood Adv. 2020 Jun 9;4(11):2489-2500. doi: 10.1182/bloodadvances.2020001441.
Mycosis fungoides (MF) is a slowly progressive cutaneous T-cell lymphoma (CTCL) for which there is no cure. In the early plaque stage, the disease is indolent, but development of tumors heralds an increased risk of metastasis and death. Previous research into the genomic landscape of CTCL revealed a complex pattern of >50 driver mutations implicated in more than a dozen signaling pathways. However, the genomic mechanisms governing disease progression and treatment resistance remain unknown. Building on our previous discovery of the clonotypic heterogeneity of MF, we hypothesized that this lymphoma does not progress in a linear fashion as currently thought but comprises heterogeneous mutational subclones. We sequenced exomes of 49 cases of MF and identified 28 previously unreported putative driver genes. MF exhibited extensive intratumoral heterogeneity (ITH) of a median of 6 subclones showing a branched phylogenetic relationship pattern. Stage progression was correlated with an increase in ITH and redistribution of mutations from stem to clades. The pattern of clonal driver mutations was highly variable, with no consistent mutations among patients. Similar intratumoral heterogeneity was detected in leukemic CTCL (Sézary syndrome). Based on these findings, we propose a model of MF pathogenesis comprising divergent evolution of cancer subclones and discuss how ITH affects the efficacy of targeted drug therapies and immunotherapies for CTCL.
蕈样肉芽肿(MF)是一种慢性进行性皮肤 T 细胞淋巴瘤(CTCL),目前尚无治愈方法。在早期斑块阶段,疾病呈惰性,但肿瘤的发展预示着转移和死亡的风险增加。先前对 CTCL 基因组景观的研究揭示了涉及十几个信号通路的>50 个驱动突变,然而,控制疾病进展和治疗耐药性的基因组机制仍不清楚。基于我们之前对 MF 克隆异质性的发现,我们假设这种淋巴瘤不是像目前认为的那样呈线性进展,而是由异质性的突变亚克隆组成。我们对 49 例 MF 进行了外显子组测序,确定了 28 个以前未报道的潜在驱动基因。MF 表现出广泛的肿瘤内异质性(ITH),中位数为 6 个亚克隆,呈分支进化关系模式。疾病进展与 ITH 的增加以及突变从主干到分支的重新分布相关。克隆驱动突变的模式高度可变,患者之间没有一致的突变。在白血病 CTCL(Sézary 综合征)中也检测到类似的肿瘤内异质性。基于这些发现,我们提出了一个 MF 发病机制模型,包括癌症亚克隆的发散进化,并讨论了 ITH 如何影响 CTCL 的靶向药物治疗和免疫治疗的疗效。